Science and Research

PACE-LUNG

Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment

Study details
Study-ID: NCT05281406, 2019-004757-88
Study-ID: NCT05281406, 2019-004757-88
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - public
Funding: Externally - public
DZL Participating Sites: CPC-M, BIH / Charité - Associated Partner, TLRC
DZL Participating Sites: CPC-M, BIH / Charité - Associated Partner, TLRC
Start Date: 12.11.2021
Completion Date: 31.12.2027
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.